Video

Dr. Chi on the Rationale for the PC-BETS Study With ctDNA in Prostate Cancer

Author(s):

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, discusses clinical challenges in prostate cancer.

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, chief medical officer and vice president, BC Cancer, medical oncologist, BC Cancer, professor, Department of Medicine, University of British Columbia, discusses clinical challenges in prostate cancer.

One of the greatest challenges in prostate cancer has always been the ability to obtain tissue, whether its archival or tissue from fresh biopsies, says Chi. Going along with this, in several PARP inhibitor trials, investigators were unable to obtain either positive or negative results from assays due to inadequate tissue samples, explains Chi.

It’s now widely understood that biopsies are often challenging for patients with prostate cancer, especially those with bone metastases, adds Chi. With these patients, it can be particularly difficult to obtain efficient samples.

In the prostate cancer biomarker enrichment and treatment selection (PC-BETS) study, investigators evaluated antitumor activity of novel targeted therapies in patients with metastatic castration-resistant prostate cancer. In this umbrella trial, circulating tumor DNA (ctDNA) was used from the start, explains Chi. Graciously, a majority of the patients, even those with advanced disease following disease progression on 1 or 2 lines of therapy, had an abundance of ctDNA available for analysis, Chi concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity